HER2

Related by string. Her2 * * HER2 positive breast cancer . HER2 positive . HER2 negative . HER2 positivity . HER2 protein . HER2 + . HER2 positive metastatic breast . HER2 gene . HER2 receptor . HER2 positive tumors . metastatic HER2 negative . metastatic HER2 positive . HER2 receptors . HER2 expression . HER2 positive breast . HER2 overexpression . Her2 positive . advanced HER2 positive *

Related by context. All words. (Click for frequent words.) 76 EGFR 68 HER2/neu 67 HER-2/neu 67 CD# [002] 66 epidermal growth 66 estrogen receptor 66 Her2 66 HER2 positive 66 HER2 receptor 66 HER2 protein 65 EGFr 65 FLT3 64 tumor cells 64 HER2 gene 64 HER3 63 estrogen receptor progesterone receptor 63 mesothelin 63 estrogen receptor ER 63 EGFR protein 63 factor receptor 63 ErbB2 63 WT1 63 trastuzumab 62 BCR ABL 62 EpCAM 62 gene amplification 62 IGF 1R 61 HER2 negative 61 HER2 overexpression 61 EGFRvIII 61 LHRH receptor 61 ERCC1 61 Her2/neu 61 KRAS 61 Stat5 61 breast cancers 61 breast tumors 61 KRAS mutation 61 tumor antigen 61 cyclin D1 60 MUC1 60 immunohistochemistry 60 caveolin 1 60 MAGE A3 60 EGFR mutation 60 clusterin 60 BRCA1 60 ERBB2 60 vimentin 60 VEGF receptor 60 GM CSF 60 progesterone receptor 60 thyroglobulin 60 EGF receptor 60 breast carcinomas 59 HER2 receptors 59 T#I [002] 59 Bcr Abl 59 GPNMB 59 CXCR4 59 uPAR 59 BRAF mutation 59 estrogen receptor alpha 59 factor receptor EGFR 59 VEGFR 59 EGFR gene 59 tumors 59 CTLA 4 58 SPINK1 58 trastuzumab Herceptin 58 metastatic breast cancer 58 hCG beta 58 HER2 + 58 HER1 58 K ras mutations 58 HER2 positive metastatic breast 58 metastatic renal cell carcinoma 58 EGFR mutations 58 Akt activation 58 molecularly targeted 58 ErbB2 positive 58 hENT1 58 HER2 positive breast cancer 58 Epidermal Growth Factor Receptor 58 specific antigen 58 survivin 58 VEGFR2 58 EGFR inhibitors 58 Clusterin 58 EGFR tyrosine kinase inhibitors 58 PCa 58 GSTP1 58 poly ADP ribose polymerase 58 IGF IR 58 HERmark 58 mRCC 57 EphA2 57 KRAS mutations 57 TNFa 57 AGTR1 57 cyclin E 57 PKCi 57 miRNA 57 oncogene 57 Akt1 57 oncoprotein 57 MDM2 57 B CLL 57 Foxp3 57 breast carcinoma 57 heterodimers 57 Src 57 NSCLC 57 c MYC 57 methylation 57 CTGF 57 MMP9 57 autoantibody 57 PTEN gene 57 HER2 positive tumors 57 TNF α 57 Her-2/neu 57 prostate specific 57 UGT#A# 57 HGF 57 carcinoembryonic antigen CEA 57 E#F# 57 T DM1 57 neoadjuvant chemotherapy 57 humanized antibody 57 CDK4 57 PC3 cells 57 tumorigenic 57 STAT3 57 overexpression 57 pancreatic cancers 57 estrogen receptors 57 MGMT gene 57 FGFR1 57 EphB4 56 VEGF 56 hormone receptor positive 56 epithelial tumors 56 isoform 56 Aurora kinase 56 Gefitinib 56 predictive biomarker 56 Bcl 2 56 melanoma tumors 56 aromatase 56 tyrosine kinase inhibitors 56 EGF receptors 56 JAK2 56 GRP# 56 PARP inhibitors 56 Akt 56 CanAg 56 autoantibodies 56 CD# antibody [001] 56 Herceptin 56 hTERT 56 tyrosine kinase inhibitor 56 CD# protein 56 Ki# 56 bcl 2 56 operable breast cancer 56 BRCA2 56 prostate tumor 56 pDCs 56 p# [001] 56 ErbB3 56 mutational status 56 cisplatin 56 K RAS 56 TRAIL receptor 56 Erlotinib 56 cancerous cells 56 immunohistochemical 56 TAp# 56 interferon IFN 56 TOP2A 56 ErbB 56 HER2 expression 56 metastasis 56 miRNAs 56 kinase inhibitors 56 E cadherin 56 activin 56 PARP inhibitor 56 prognostic markers 56 recurrent ovarian cancer 56 miR #a [002] 56 pertuzumab 56 cytotoxicity 56 estrogen receptor positive 56 c myc 56 leukemic cells 56 HAAH 56 B7 H3 56 PIK3CA 56 metastatic 56 androgen receptor AR 56 bevacizumab Avastin 56 myeloma cells 56 receptor tyrosine kinase 56 lymph node metastasis 56 chemosensitivity 55 c MET 55 pancreatic adenocarcinoma 55 imatinib Gleevec 55 carcinoembryonic antigen 55 iNOS 55 tumor suppressor gene 55 NFkB 55 GBM tumors 55 bortezomib 55 BRAF mutations 55 chemotherapeutic agents 55 IMC A# 55 annexin V 55 FISH fluorescence 55 tyrosine kinase 55 immunohistochemical staining 55 K ras 55 oncogenes 55 solid tumors 55 mutant p# 55 NSCLC tumors 55 EZH2 55 oncoproteins 55 CYP#C# [001] 55 BRAF gene 55 vascular endothelial growth 55 lymph node metastases 55 epithelial ovarian cancer 55 S#A# [002] 55 KRAS status 55 BRCA1 gene 55 lapatinib 55 Trastuzumab 55 PDGF receptor 55 xenograft models 55 vWF 55 ovarian cancers 55 castration resistant prostate cancer 55 cetuximab 55 mRNA expression 55 luteinizing hormone releasing 55 pCR 55 peptide antigens 55 FOXP3 55 Syk 55 TLE3 55 distant metastasis 55 antibody 55 antigen PSA 55 interferon 55 PLX# 55 activating mutations 55 Bortezomib 55 metastatic disease 55 CLL cells 55 prostate cancers 55 Recurrence Score 55 Factor Receptor 55 GLI1 55 antigen 55 colon carcinoma 55 EGFR pathway 55 EGFR receptor 55 PI3 kinase 55 beta catenin 54 HBsAg 54 Zolinza 54 constitutively 54 cytokeratin 54 HER2 ErbB2 54 CD# + [002] 54 SOD1 54 eIF4E 54 erlotinib Tarceva ® 54 grade cervical intraepithelial 54 homodimer 54 hypermethylation 54 decitabine 54 metastases 54 homodimers 54 Pertuzumab 54 oncogenic 54 androgen receptors 54 adjuvant therapy 54 olaparib 54 androgen receptor 54 gefitinib 54 Skp2 54 CD#L 54 FDG PET 54 pro angiogenic 54 progesterone receptor PR 54 nucleolin 54 activated lymphocytes 54 hedgehog pathway 54 p#INK#a 54 PGE2 54 induce apoptosis 54 cytokine 54 TNFalpha 54 HER2 neu 54 ERa 54 XIAP 54 prostate cancer AIPC 54 overexpressed 54 EGFR TKI 54 RRM1 54 glioma cells 54 MAPK 54 ovarian carcinoma 54 relapsed ovarian cancer 54 keratinocyte 54 PPARgamma 54 NF kB 54 T#I mutation 54 B7 H4 54 fulvestrant 54 Myc 54 renal cell carcinoma 54 progesterone receptor negative 54 B7 H1 54 TACE 54 cytotoxic 54 monoclonal antibody 54 Lp PLA2 54 activating mutation 54 NF kB pathway 54 enzymatic activity 54 galectin 3 54 temsirolimus 54 VEGF inhibitors 54 CEACAM1 54 Imatinib 54 IGFBP 54 BRCA mutation 54 overexpress 54 haematopoietic 54 Bevacizumab 54 BRCA 54 endocrine therapy 54 neuroblastoma cells 54 thymidylate synthase TS 54 MAb 54 chemotherapeutic agent 54 immunoreactivity 54 KRAS gene 54 panobinostat 54 ALDH 54 laminin 54 macrophage colony stimulating 54 metastatic colorectal cancer 54 gastrointestinal stromal tumors 54 HIF 1a 54 ER alpha 54 tyrosine phosphorylation 54 hepatocellular carcinoma 54 IL# [001] 54 ABCB1 54 NMP# 54 Bezielle 54 metastatic prostate cancer 54 receptors EGFR 54 CD4 + CD# 54 CD# antigen 54 HRPC 54 effector function 54 prognostic 53 TrkA 53 IFN gamma 53 PDGFR 53 mTOR 53 interferon beta 53 hormone LHRH 53 ubiquitination 53 metastatic melanomas 53 CaP 53 erlotinib 53 CD#b 53 overexpress HER2 53 LHRH 53 liver metastases 53 medullary thyroid cancer 53 kinase 53 NPM1 53 HPV 53 HIF 1alpha 53 sunitinib 53 CCR5 53 colorectal carcinoma 53 glioblastoma 53 tumor hypoxia 53 AT1R 53 HGS ETR1 53 HER2 positive cancers 53 histone deacetylases 53 TGF β 53 IL #R 53 PI3K inhibitor 53 endometrial 53 thyroid stimulating hormone 53 immunohistochemistry IHC 53 chemoresistance 53 tumor progression 53 CYP#D# 53 VEGFR1 53 FasL 53 endoxifen 53 P cadherin 53 Flt3 53 glioblastoma cells 53 IL 1ß 53 p# MAPK 53 mutated K ras 53 miR #b [002] 53 Vorinostat 53 tumorigenesis 53 qRT PCR 53 docetaxel 53 FGFR2 53 neoadjuvant therapy 53 heparanase 53 PlGF 53 biomarker 53 adipogenic 53 microRNA miR 53 HLA DR 53 dasatinib 53 Bcl xL 53 MET amplification 53 peripheral blood mononuclear 53 selective inhibitors 53 angiogenesis inhibitor 53 miR #b [001] 53 phosphorylated 53 genomic alterations 53 GnRH agonists 53 prognostic factor 53 PARP inhibition 53 estrogen progesterone 53 mutated KRAS gene 53 trastuzumab Herceptin ® 53 eNOS 53 B Raf 53 tamoxifen 53 PDE7B 53 tumor suppressor 53 IgG 53 K ras mutation 53 follicle stimulating hormone 53 alkylating agents 53 immunostaining 53 NPM1 mutation 53 doxorubicin 53 distant metastases 53 Vectibix 53 antisense oligonucleotides 53 somatic mutations 53 axillary lymph nodes 53 anthracyclines 53 immunohistochemical analysis 53 transgene expression 53 DHFR 53 HGPIN 53 TGF beta 53 CCR7 53 N cadherin 53 malignant cells 53 biomarkers 53 serum prostate 53 CYP3A 53 YONDELIS 53 IGFBP2 53 KRAS oncogene 53 tumor recurrence 53 prostate tumors 53 p# protein 53 p# Shc 53 prostate specific antigen 53 kinase inhibitor 53 BRAF V#E mutation 53 imatinib 53 tumor microenvironment 53 anticancer therapies 53 TNFα 53 BRCA mutations 53 MAPK pathway 53 E selectin 53 neoplastic 53 bone metastasis 53 Cetuximab 53 Mcl 1 53 Herceptin trastuzumab 53 neoadjuvant 53 miR #a [001] 53 thymidylate synthase 53 hypoxia inducible factor 53 HDAC6 53 constitutively activated 53 GATA3 53 TGFβ 53 MMP2 53 GRK2 53 tumor angiogenesis 53 aneuploidy 53 RASSF1A 53 azacitidine 53 microRNA 53 interferon gamma 53 SIRT2 53 nestin 53 NY ESO 53 caspase 53 alpha folate receptor 53 FGFR4 53 estrogen receptor beta 53 interferon alfa 53 seliciclib 53 prostate tissue 52 nilotinib 52 imatinib therapy 52 RANKL 52 tumor suppressor protein 52 lymphomas 52 metastatic RCC 52 lactate dehydrogenase LDH 52 angiogenic 52 CD# receptor 52 MDR1 52 Gleevec resistant 52 uPA 52 histological subtype 52 HPV# 52 CDKs 52 TRAIL induced apoptosis 52 gastrin 52 interferon alpha 52 Immunohistochemical analysis 52 IgG1 monoclonal antibody 52 transfected 52 myeloid cells 52 promoter methylation 52 RANK ligand 52 SATB1 52 VIDAZA 52 P selectin 52 IL 1beta 52 MYCN 52 HDAC 52 IGF1R 52 micrometastases 52 follicular lymphoma 52 antiangiogenic therapy 52 ZNF# 52 gastrointestinal stromal tumors GIST 52 EGFR HER2 52 HCV replicon 52 folate receptor 52 depsipeptide 52 calcitriol 52 ImmuKnow 52 breast epithelial cells 52 microRNAs 52 cystatin C 52 serotonin receptor 52 beta subunit 52 cisplatin resistant 52 flavopiridol 52 metastatic melanoma 52 gastrointestinal stromal tumor GIST 52 castrate resistant 52 TRAIL R2 52 IFN α 52 LNCaP cells 52 CYP# [002] 52 HSP# 52 topoisomerase 52 methylated DNA 52 carcinomas 52 p# biomarker 52 glioblastomas 52 MEK1 52 allogeneic SCT 52 BRAF 52 splice variants 52 FGFR 52 LKB1 52 surface glycoprotein 52 antitumor activity 52 selective inhibitor 52 myelofibrosis polycythemia vera 52 cMET 52 β catenin 52 anti apoptotic 52 VEGF expression 52 micrometastasis 52 TIMP 1 52 gp# [001] 52 FUS1 52 ovarian tumors 52 inhibiting tumor 52 beta galactosidase 52 gefitinib Iressa 52 proto oncogene 52 adjuvant radiation 52 anti CD3 52 ERK1 2 52 ovarian cancer 52 bevacizumab 52 prognostic indicator 52 interleukins 52 CIN2 + 52 xenografts 52 p#NTR 52 grade gliomas 52 Rap1 52 deacetylation 52 cervical carcinoma 52 tumor vasculature 52 selective inhibition 52 costimulation 52 CD# + [001] 52 natriuretic peptide 52 targeting CD# 52 atypia 52 mutated KRAS 52 endoglin 52 EGFR expression 52 RBP4 52 lymph node involvement 52 bispecific antibody 52 anticancer agents 52 Irinotecan 52 estrogen receptor negative 52 invasive lobular carcinoma 52 antiangiogenic 52 protein kinases 52 breast cancer subtypes 52 predictive biomarkers 52 SERMs 52 tumor suppressor genes 52 urothelial carcinoma 52 TTR gene 52 BRCA deficient 52 prognostic marker 52 HEK# cells 52 anti apoptotic proteins 52 metastatic colorectal 52 Tumor Necrosis Factor 52 gp# [002] 52 BAY #-# 52 endocrine therapies 52 Notch1 52 metastatic cancer 52 platelet reactivity 52 P#X# 52 tumoral 52 syngeneic 52 vandetanib 52 Cytochrome P# 52 melanocyte 52 DNA methylation 52 p# mutation 52 pro apoptotic 52 NF kappa B 52 PPAR gamma 52 Wnt#b 52 Azacitidine 52 Th2 cells 52 MetMAb 52 cyclooxygenase 2 52 tumorigenicity 52 mAb 52 Hedgehog pathway 52 rhIL 7 52 miR 52 somatostatin receptors 52 PDGF B 52 androgen 52 PKC delta 52 KIT mutations 52 epithelial cancers 52 colorectal tumor 52 GISTs 52 TGF β1 52 PKM2 52 small molecule inhibitors 52 Lapatinib 52 lobular carcinoma 52 IGFBP 3 52 invasive carcinoma 52 IgG antibodies 52 tumor 52 JAK3 52 IL #E 52 MIF protein 52 taxane therapy 52 CXCL# 52 5FU 52 eIF 4E 52 gastric cancer 52 IFN beta 52 Nampt 52 Trp p8 52 Lymph node 52 malignant pleural mesothelioma 52 sFlt 1 52 factor G CSF 52 MSH2 52 TLR2 52 cyclooxygenase 52 inducible nitric oxide synthase 52 Li Fraumeni 52 H#K#me# 52 adjuvant chemotherapy 52 p# activation 51 neuroendocrine tumors 51 CpG 51 hereditary breast cancer 51 anaplastic lymphoma kinase 51 metastatic tumors 51 BCR ABL protein 51 adecatumumab 51 topotecan 51 alpha fetoprotein AFP 51 mRNAs 51 serous ovarian cancer 51 tryptase 51 TG2 51 dimerization 51 NFκB 51 IRESSA 51 histologies 51 prostate cancer CaP 51 adhesion molecule 51 proapoptotic 51 mAbs 51 LRP6 51 peritoneal carcinomatosis 51 TSLP 51 ApoB 51 HBV DNA 51 FGFR3 51 selective agonist 51 TKI therapy 51 TGFß 51 selective modulator 51 IgM 51 PTPN# 51 tumor antigens 51 colorectal liver metastases 51 GSTT1 51 metastatic lesions 51 platelet aggregation 51 ERalpha 51 aromatase inhibitor 51 A3 adenosine receptor 51 Dasatinib 51 antitumor effect 51 PPAR γ 51 TLR3 51 azacytidine 51 GM CSF granulocyte 51 cytogenetic 51 cediranib 51 tumor necrosis 51 Tregs 51 interleukin IL -# 51 receptor tyrosine kinase inhibitor 51 IgG antibody 51 osteopontin 51 medulloblastoma 51 PECAM 1 51 Wwox 51 hepatoma 51 Epratuzumab 51 mRNA 51 prostate adenocarcinoma 51 thymocytes 51 apoptotic 51 biodistribution 51 Tie2 51 HDACs 51 ADAMTS# 51 alternatively spliced 51 situ hybridization 51 Ceflatonin 51 etoposide 51 5 Fluorouracil 51 kinases 51 protein tyrosine phosphatase 1B 51 K ras gene 51 mesenchymal cells 51 angiogenesis 51 thymalfasin 51 TGF ß 51 ncRNAs 51 protein kinase C 51 aromatase inhibitors 51 endostatin 51 M2 subunit 51 p# deficient 51 CD# CD# 51 ß catenin 51 neurite outgrowth 51 inactivating mutations 51 colorectal cancers 51 recombinant erythropoietin 51 neuroblastoma tumors 51 leukemic cell 51 GNAQ 51 ApoE4 51 Notch receptors 51 apoptotic pathway 51 beta actin 51 induces apoptosis 51 antisense 51 Pralatrexate 51 NKG2D 51 NQO1 51 multikinase inhibitors 51 colon cancers 51 CCN2 51 intracellular signaling 51 Docetaxel 51 XBP1 51 Prostate Specific Antigen PSA 51 TERT 51 cathepsin B 51 fludarabine 51 mitogen activated protein kinase 51 liposomal doxorubicin 51 EpCAM expression 51 HLA antibody 51 androgen independent 51 HCV 51 BMP2 51 MAbs 51 #F FDG 51 paclitaxel Taxol 51 preoperative chemotherapy 51 Smoothened 51 hepatocyte 51 phosphorylation 51 Cyclin E 51 atypical hyperplasia 51 CD# molecule 51 procaspase 3 51 MAP kinase 51 NGAL 51 TIMP 51 pegylated liposomal doxorubicin 51 N Myc 51 HDAC2 51 DNA methyltransferases 51 Immunohistochemical staining 51 MicroRNA 51 micro RNAs 51 proteolytic cleavage 51 Mdm2 51 interleukin 51 cilengitide 51 HER2/neu protein 51 BCL#A 51 COX2 51 quantitative PCR 51 ADAM# 51 BCL2 51 gastrointestinal stromal tumors GISTs 51 IgG1 antibody 51 Aliskiren 51 chemokine receptor 51 thymosin 51 malignant lesions 51 cell lymphomas 51 prostate carcinoma 51 sorafenib 51 GHRH 51 MDSCs 51 androgens 51 single nucleotide polymorphism 51 PI3K Akt 51 sarcosine 51 RAR beta 51 delta isoform 51 AAV2 51 ixabepilone 51 immunoglobulin G 51 mTOR pathway 51 PPAR 51 SOX9 51 OncoVEX GM CSF 51 CCL# 51 contralateral breast 51 ovarian 51 CD# antibodies 51 apoptotic cells 51 anticancer therapy 51 HSCs 51 IDH1 51 5alpha reductase 51 EUS FNA 51 Smad3 51 chronic lymphocytic leukemia CLL 51 carcinoid tumors 51 CCR2 51 PTEN 51 downregulated 51 chemotherapeutic 51 lung tumors 51 IFNg 51 E cadherin expression 51 BRAF protein 51 NRG1 51 sipuleucel T 51 polymorphisms 51 HER2 amplification 51 tumor subtypes 51 effector memory 51 CYC# 51 intratumoral injection 51 downstream effectors 51 HepG2 cells 51 inhibitory activity 51 FCGR3A 51 Cyclin D1 51 CD#c 51 beta1 integrin 51 bleomycin 51 MGd 51 GPC3 51 FOXO3a 51 VKORC1 51 HLA B# 51 angiotensin II 51 EGFR HER 51 chimeric monoclonal antibody 51 effector functions 51 Lenalidomide 51 transfected cells 51 cytokine secretion 51 plasminogen 51 gastric cancers 51 PITX2 methylation 51 Nedd4 51 panitumumab Vectibix 51 SGK1 51 apolipoproteins 51 Fludara ® 51 MUC1 * 51 CD1d 51 miRNA genes 51 abnormal cytology 51 HER2 HER3 51 nutlin 3a 51 quantitative RT PCR 51 KRAS wild 51 catenin 51 p#Kip# 51 peginterferon 51 tyrosine kinase receptor 51 colorectal cancer 51 virologic failure 51 tumor biopsies 51 inhibitor RG# 51 dsRNA 51 IFN alpha 51 HDAC inhibitors 51 colorectal carcinomas 51 lymphocytes 51 ENMD # 51 CCX# 51 bevacizumab Avastin ® 51 FOLFOX6 51 malignant ascites 51 Notch pathway 51 anti EGFR antibody 51 PI3K pathway 51 nonsmall cell lung cancer 51 Th# cells 51 UsiRNAs 51 p tau 51 thrombin receptor 50 RANK Ligand 50 pancreatic tumor 50 calcineurin 50 peptide BNP 50 investigational humanized monoclonal antibody 50 carcinoma 50 Th2 50 anticancer drugs 50 PI3K inhibitors 50 humanized anti

Back to home page